Summit Tx Capital, L.P. Alnylam Pharmaceuticals, Inc. Call Options Transaction History
Summit Tx Capital, L.P.
- $2.32 Trillion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ALNY
# of Institutions
721Shares Held
111MCall Options Held
978KPut Options Held
881K-
Capital World Investors Los Angeles, CA16.7MShares$5.39 Billion0.76% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$4.21 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$3.07 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.15MShares$2.3 Billion0.44% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.42MShares$1.42 Billion0.79% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $39.6B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...